G
Ganymede
Low-code PaaS for biotech software engineering that enables users to connect apps, ingest data, and construct pipelines
About Ganymede
Ganymede.bio is a cloud-based platform that specializes in scientific data and instrument connectivity. The company's primary focus is to streamline and automate data management for scientists, saving them up to 20% of their time. Ganymede achieves this by integrating various lab instruments and applications into a single, accessible data layer. This eliminates the need for manual data entry and file management, thereby increasing efficiency and productivity.
Read full description
The company's unique Lab-as-Code technology powers this data automation, providing rich, compliant data that can be used for artificial intelligence and machine learning applications. Ganymede's platform is versatile, capable of connecting to any instrument or application and transforming the data into a cloud-based format that is ready for automation and analysis.
Ganymede's platform is designed to serve clients in the scientific and research industry, particularly those who are looking to modernize their data management systems. The company's business model is based on providing a comprehensive solution for lab data integration and automation. They generate revenue by offering their platform as a service, which can be customized to meet the specific needs of each client.
Ganymede's platform also ensures that all data is FAIR (Findable, Accessible, Interoperable, and Reusable), making it easy for scientists to locate and use the data they need. This is achieved by parsing raw data, metadata, and results into structured tables. The platform also offers robust data compliance features, including context, traceability, and versioning, which go beyond basic audit logs to provide full data flow reproducibility.
At a glance
- Status
- Acquired
- Founded
- 2022
- Headquarters
- Palo Alto, United States
- Employees
- 42
- Open positions
- 1
- Dealroom signal
- 57.6/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- SaaS
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Ganymede.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jan 2026 | $0 | — | Apprentice | ↗ |
| SERIES A✓Equity / VC | Dec 2022 | $13M | $51M | Caffeinated Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Ganymede is 2.2K monthly website visits, down 50% over the last three months. Ganymede's team declined 27.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
BoxGroup
SciFi VC
Caffeinated
Series A1 investor entered at this stage
Other known investors2 additional known investors
Apprentice
Hawktail
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ganymede on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ganymede’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.